Vivo Bio Tech Intrinsic Value
VIVOBIOT Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹39.60 | ₹31.68 - ₹47.52 | +50.3% | EPS: ₹1.80, Sector P/E: 22x |
| Book Value Method | asset | ₹65.88 | ₹59.29 - ₹72.47 | +150.0% | Book Value/Share: ₹45.88, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹52.70 | ₹47.43 - ₹57.97 | +100.0% | Revenue/Share: ₹30.59, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹52.70 | ₹47.43 - ₹57.97 | +100.0% | EBITDA: ₹24.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹65.53 | ₹52.42 - ₹78.64 | +148.7% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹11.52 | ₹10.37 - ₹12.67 | -56.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹27.81 | ₹25.03 - ₹30.59 | +5.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹23.53 | ₹21.18 - ₹25.88 | -10.7% | ROE: 5.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹43.11 | ₹38.80 - ₹47.42 | +63.6% | EPS: ₹1.80, BVPS: ₹45.88 |
Want to compare with current market value? Check VIVOBIOT share price latest .
Valuation Comparison Chart
VIVOBIOT Intrinsic Value Analysis
What is the intrinsic value of VIVOBIOT?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vivo Bio Tech (VIVOBIOT) is ₹43.11 (median value). With the current market price of ₹26.35, this represents a +63.6% variance from our estimated fair value.
The valuation range spans from ₹11.52 to ₹65.88, indicating ₹11.52 - ₹65.88.
Is VIVOBIOT undervalued or overvalued?
Based on our multi-method analysis, Vivo Bio Tech (VIVOBIOT) appears to be trading below calculated value by approximately 63.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.11 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 5.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 41.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.36x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Vivo Bio Tech
Additional stock information and data for VIVOBIOT
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹12 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹16 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹15 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹14 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |